Stephen Feider Sells 4,896 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 4,896 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $17.03, for a total value of $83,378.88. Following the completion of the transaction, the chief financial officer owned 165,931 shares of the company’s stock, valued at approximately $2,825,804.93. This represents a 2.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Feider also recently made the following trade(s):

• On Friday, June 26th, Stephen Feider sold 5,104 shares of Beta Bionics stock. The stock was sold at an average price of $17.05, for a total transaction of $87,023.20.
• On Tuesday, June 2nd, Stephen Feider sold 6,676 shares of Beta Bionics stock. The shares were sold at an average price of $12.61, for a total transaction of $84,184.36.

Beta Bionics Trading Up 6.6%

Shares of NASDAQ:BBNX opened at $16.70 on Thursday. The company has a 50 day moving average of $12.36 and a 200 day moving average of $15.22. The stock has a market cap of $744.15 million, a P/E ratio of -11.06 and a beta of 3.02. Beta Bionics, Inc. has a 12 month low of $8.80 and a 12 month high of $32.71.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The business had revenue of $27.63 million for the quarter. On average, equities analysts forecast that Beta Bionics, Inc. will post -2.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Beta Bionics

Hedge funds have recently made changes to their positions in the business. Strs Ohio bought a new position in shares of Beta Bionics during the 1st quarter valued at $29,000. EverSource Wealth Advisors LLC lifted its stake in Beta Bionics by 203.6% in the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after purchasing an additional 1,594 shares during the last quarter. Summit Securities Group LLC bought a new stake in Beta Bionics in the fourth quarter worth $52,000. Legal & General Group Plc boosted its position in Beta Bionics by 197.4% during the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after buying an additional 2,639 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its position in Beta Bionics by 1,075.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after buying an additional 1,818 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BBNX. Stifel Nicolaus lowered their price target on Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Leerink Partners cut their price objective on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. Wall Street Zen cut shares of Beta Bionics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. Weiss Ratings downgraded shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Finally, The Goldman Sachs Group lowered their target price on shares of Beta Bionics from $19.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Beta Bionics currently has an average rating of “Moderate Buy” and a consensus price target of $19.70.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.